Cronos Group (NASDAQ: CRON) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its peers? We will compare Cronos Group to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, valuation, dividends and institutional ownership.
This is a summary of recent ratings for Cronos Group and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cronos Group Competitors||135||357||403||14||2.33|
Cronos Group presently has a consensus price target of $9.83, suggesting a potential upside of 96.27%. As a group, “Medicinals & botanicals” companies have a potential upside of 118.46%. Given Cronos Group’s peers higher probable upside, analysts plainly believe Cronos Group has less favorable growth aspects than its peers.
Earnings and Valuation
This table compares Cronos Group and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cronos Group||$25.64 million||$1.17 billion||7.48|
|Cronos Group Competitors||$219.25 million||-$99.48 million||2.15|
Cronos Group’s peers have higher revenue, but lower earnings than Cronos Group. Cronos Group is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
12.1% of Cronos Group shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 7.9% of Cronos Group shares are owned by company insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Cronos Group and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cronos Group Competitors||-1,150.45%||-258.05%||-48.97%|
Volatility and Risk
Cronos Group has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Cronos Group’s peers have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.
Cronos Group beats its peers on 7 of the 13 factors compared.
Cronos Group Company Profile
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.